Anke E Kip
Overview
Explore the profile of Anke E Kip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belien J, Kip A, Swertz M
BMJ Open Sci
. 2022 May;
6(1):e100268.
PMID: 35505836
Objective: This study investigates current standards and operational gaps in the management and sharing of next generation sequencing (NGS) data within the healthcare and research setting and according to Findable,...
2.
Kip A, Blesson S, Alves F, Wasunna M, Kimutai R, Menza P, et al.
J Antimicrob Chemother
. 2021 Mar;
76(5):1258-1268.
PMID: 33677546
Background: Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial...
3.
Verrest L, Kip A, Musa A, Schoone G, Schallig H, Mbui J, et al.
Clin Infect Dis
. 2021 Feb;
73(5):775-782.
PMID: 33580234
Background: To expedite the development of new oral treatment regimens for visceral leishmaniasis (VL), there is a need for early markers to evaluate treatment response and predict long-term outcomes. Methods:...
4.
Palic S, Kip A, Beijnen J, Mbui J, Musa A, Solomos A, et al.
J Antimicrob Chemother
. 2020 Aug;
75(11):3260-3268.
PMID: 32780098
Background: Conventional miltefosine dosing (2.5 mg/kg/day) for treatment of visceral leishmaniasis (VL) is less effective in children than in adults. A higher allometric dose (median 3.2 mg/kg/day) was therefore investigated...
5.
Mbui J, Olobo J, Omollo R, Solomos A, Kip A, Kirigi G, et al.
Clin Infect Dis
. 2018 Sep;
68(9):1530-1538.
PMID: 30188978
Background: Convenient, safe, and effective treatments for visceral leishmaniasis in Eastern African children are lacking. Miltefosine, the only oral treatment, failed to achieve adequate efficacy, particularly in children, in whom...
6.
Kip A, Wasunna M, Alves F, Schellens J, Beijnen J, Musa A, et al.
Front Cell Infect Microbiol
. 2018 Jun;
8:181.
PMID: 29911074
The parasite resides and replicates within host macrophages during visceral leishmaniasis (VL). This study aimed to evaluate neopterin, a marker of macrophage activation, as possible pharmacodynamic biomarker to monitor VL...
7.
Kip A, Castro M, Gomez M, Cossio A, Schellens J, Beijnen J, et al.
J Antimicrob Chemother
. 2018 May;
73(8):2104-2111.
PMID: 29757380
Objectives: Leishmania parasites reside within macrophages and the direct target of antileishmanial drugs is therefore intracellular. We aimed to characterize the intracellular PBMC miltefosine kinetics by developing a population pharmacokinetic...
8.
Dorlo T, Kip A, Younis B, Ellis S, Alves F, Beijnen J, et al.
J Antimicrob Chemother
. 2017 Sep;
72(11):3131-3140.
PMID: 28961737
Background: Low efficacy of miltefosine in the treatment of visceral leishmaniasis was recently observed in Eastern Africa. Objectives: To describe the pharmacokinetics and establish a pharmacokinetic/pharmacodynamic relationship for miltefosine in...
9.
Kip A, Schellens J, Beijnen J, Dorlo T
Clin Pharmacokinet
. 2017 Jul;
57(2):151-176.
PMID: 28756612
This review describes the pharmacokinetic properties of the systemically administered antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and amphotericin B (AMB), including their absorption, distribution, metabolism and excretion and potential...
10.
Castro M, Gomez M, Kip A, Cossio A, Ortiz E, Navas A, et al.
Antimicrob Agents Chemother
. 2016 Dec;
61(3).
PMID: 27956421
An open-label pharmacokinetics (PK) clinical trial was conducted to comparatively assess the PK and explore the pharmacodynamics (PD) of miltefosine in children and adults with cutaneous leishmaniasis (CL) in Colombia....